

DESCRIPTION

Species Reactivity	Human
Specificity	Detects Human CTLA-4 based on Ipilimumab therapeutic antibody.
Source	Recombinant Monoclonal Human IgG ₁ Clone # Hu111
Purification	Protein A or G purified from cell culture supernatant
Immunogen	Human CTLA-4
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.


APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the Technical Information section on our website.

	Recommended Concentration	Sample
Flow Cytometry	0.25 µg/10 ⁶ cells	See Below
CyTOF-ready	Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.	

DATA

Flow Cytometry



Detection of CTLA-4 in HEK293 Human cell line Transfected with Human CTLA-4 and eGFP by Flow Cytometry HEK293
Human cell line transfected with (A) Human CTLA-4 or (B) irrelevant transfectants and eGFP was stained with Human Anti-Human CTLA-4 (Ipilimumab) Monoclonal Antibody (Catalog # MAB9928) followed by APC-conjugated Anti-Human IgG Secondary Antibody (Catalog # F0135). View our protocol for [Staining Membrane-associated Proteins](#).

PREPARATION AND STORAGE

Reconstitution	Reconstitute at 0.5 mg/mL in sterile PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. <ul style="list-style-type: none"> • 12 months from date of receipt, -20 to -70 °C as supplied. • 1 month, 2 to 8 °C under sterile conditions after reconstitution. • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

BACKGROUND

Ipilimumab is a biosimilar directed against the extracellular domain of CTLA-4. This product can be used as the standard in pharmacokinetic (PK) assays.